International Journal of Clinical Research

Objective: To explore the clinical effect of flunarizine hydrochloride in the treatment of migraine. Methods: A total of 90 patients with migraine admitted to our hospital from January 2022 to December 2022 were randomly divided into a control group (n=45, nimergoline tablets) and a study group (n=45, flunarizine hydrochloride). The migraine-related symptoms and pain scores, serum indicators, hemodynamic indicators, incidence of adverse reactions, and quality of life scores were compared. Results: The frequency, duration, and pain score of migraine attacks in the study group were less (P<0.05); Research group TNF- α、 ICAM-1、CGRP、IL-1 β Both were lower, with a higher 5-HT, P<0.05; The hemodynamic indexes in the study group were lower (P<0.05); There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05); The quality of life score in the study group was higher (P<0.05). Conclusion: Flunarizine hydrochloride is effective in the treatment of migraine, improving hemodynamics, alleviating migraine symptoms, and improving quality of life.

Migraine; Flunarizine hydrochloride; Hemodynamics; Pain; Quality of life